CA
NZ
UK
AU
IND
US
● Bolt Biotherapeutics is a clinical-stage immuno-oncology company built around its Boltbody immune-stimulating antibody conjugate platform.
● Tvardi Therapeutics trades near 52-week lows, reflecting the impact of an earlier clinical setback.
● Tenax Therapeutics shares collapsed roughly 85% on August 10, 2026, one of the steepest single-day declines in the sector this year.
● Neumora Therapeutics confirmed in a June 2026 release that navacaprant is discontinued, its once-flagship depression drug.
● Health Catalyst shares plunged 25.5% to $1.71 on August 6, 2026 after second-quarter results, even thoughRevenuetechnically beat Wall Street's estimate.
● Cibus shares fell as much as roughly 16% in after-hours trading following second-quarter 2026 results released August 13, 2026.
Eton Pharmaceuticals, Inc. (NASDAQ: ETON) shares closed up 44% at $58.86 after analysts at H.C. Wainwright adjusted their price target upward to $70.00 from $65.00.
Innate Pharma (NASDAQ: IPHA) shares closed down 14% at $2.17 following the pricing of a €30 million private placement consisting of 17.65 million shares at €1.70 per share.
Capricor Therapeutics (NASDAQ: CAPR) shares closed up 58% at $6.65 following news that the FDA will evaluate supplemental deramiocel efficacy results for Duchenne muscular dystrophy.
BeyondSpring Inc. (NASDAQ: BYSI) shares closed down 16% at $0.84 even afterSubsidiarySEED Therapeutics secured FDA Orphan Drug Designation for ST-01156 to treat neuroblastoma.
Please wait processing your request...